Applied Cells is pleased to announce the expansion of the MARS® Ingenuity™ line with the addition of CD34 Nanobeads, TCR α/β Nanobeads, and CD56 Nanobeads, now available in both RUO and GMP formats. Designed for use on the MARS® Bar Platform, these new reagents broaden the portfolio for cell therapy research, process development, and manufacturing.
The expanded Ingenuity line supports streamlined cell isolation workflows across a wide range of input sample types, including Leukopak, PBMC, and whole peripheral blood. Built to help teams move from process development toward GMP manufacturing, the portfolio supports cost-effective, consistent, column-free separation workflows with the flexibility needed for evolving cell therapy applications.
The newly added reagents address important workflow needs across cell therapy development:
- CD34 Nanobeads for HSC selection
- TCR α/β Nanobeads for TCR α/β depletion
- CD56 Nanobeads for NK cell selection
Optimized for the MARS® Bar Platform, the Ingenuity line is designed to support flexible protocols, broad sample-volume compatibility, enclosed automated processing, and GMP manufacturing support. This gives cell therapy developers a practical path from early-stage workflow development to larger-scale manufacturing on a unified platform. With this portfolio expansion, Applied Cells continues to strengthen its reagent offering for cell therapy development and manufacturing.
Get in touch with a member of our team to discuss your specific reagent and workflow requirements.
Kat Ginda-Mäkelä
